Member Info for Uncanny

Me too waiting for news.

We have had enough lacklustre and disappointing news so we’re well overdue something good and price enhancing.

Whilst it is normal for VAL to spill some of the beans on product updates during presentations, lets hope for comprehensive updates with full details thereafter by RNS or it all gets lost in the wash so to speak!

VAL, 201 analysis breakdown as at end of last CT PLUS meat on the bones for 401 LOl’s and any more signees please.

We need 201 and 401 RNS’s with update, deal and what its worth. Then we will rerate IMHO

PB

How can i do that securely?

Freddie? Care to share?

Love to hear the positive parts chaps?

People just seem to be accumulating slowly whilst we wait like me.

Roll on good news....., please!

Now up to my 2% target holding and think this will come good before EOY, IMHO of course.

GLA

H2H, but 401 starts P3 next year so lets see the deals as without P3 can’t start.

Scooby, yes l expect news in Q4 on analysis and good you hear all the boxes have been ticked so far by GM.

Emailed Suzy and although she has not physically been in the office she has been keeping up to speed with developments, hence a reply to my email within 5 mins!

Ok H2H that is true, some bad deals but what if 201 gets results which show a over a 40% reduction (4mg showed -30% so what would 5mg etc up to 8mg) and stops metastatic growth as described interestingly in the recent 201 US patent and then VAL get a deal worth between £100 to £200 mn (seen much higher figures than this too)?

Then what?

Borgie, 3 years ago 201 was pre-clinical, but showing 30% reduction up to 4mg

Q3 is analysis - l am surmising we will hear Q4, but maybe EO Q3.

Suzy will be mighty peed off after 10 years of putting her heart and soul in to 401 and doubt she would just move on as you suggest without major disappointment, but guis is not the case as 2 LOI’s and early 2020 is the start of P3 with pharma partners which was RNS’d

Well let's just wait and see but ask yourselves:

Why is 401 progressing and moving to P3 early 2020 with 2 LOI’s (maybe more) if not commercial? Otherwise it would have been shelved plus Suzy has a lot to lose as she certainly has got her skin in 401.

Why has the pre-eminent oncologist, Dr Linch been appointed to 201 to further CT,s and at 4mg showing primary evidence in prostate cancer if it isn’t working?

“analysis of the data is anticipated to start Q3 2019, following which a full analysis of the results and findings will be published“

I am hoping for a stella 4th quarter, but further patience needed l guess and unfortunately depends on your average price l’m afraid to say.

DYOR and GLA. I hope it comes good for the many.

Nobody can cold call you under GPDR unless not in the Uk and so the rules don’t touch you. The question to ask is where they got your name from?

Life Sciences

I’m baffled? So the content is incorrect or there should have been more flesh on the bones l guess.

Congrats to those who managed to get in sub .14. My 1.5mn top up at .181 looking a bit sad. We must be soon to getting some more updates soon.

So the JV 101 off, but we still have FIT IP which is paramount to marry with 101. In some ways quite pleased to see the back of EHGO as l am to cur ties with SVS if they were close to the mark before any VAL commitments. They need another broker with a LS research dept now.

Obelix, l believe including the tax return, equity sale and cash in the bank VAL had circa £900k at a cash burn of £80-£90k pa which was said at the AGM just over a month ago.

The proof is in the pudding hence people seeing the opportunity to buy in cheap this morning.

Buying Volume going strong.

Nothing has changed except SVS out.

The monies are still the same but just updating to say HMRC £400k money hasn’t arrived, but will be shortly.

Lol

Nope, sorry but l would recommend to everyone to use a blue chip broker next time to avoid a beaufort, svs etc occurring again

Luck